TY - JOUR
T1 - Does extracorporeal membrane oxygenation improve survival in pediatric acute respiratory failure?
AU - Barbaro, Ryan P.
AU - Xu, Yuejia
AU - Borasino, Santiago
AU - Truemper, Edward J.
AU - Watson, R. Scott
AU - Thiagarajan, Ravi R.
AU - Wypij, David
AU - Curley, Martha A.Q.
N1 - Funding Information:
*The RESTORE (Randomized Evaluation of Sedation Titration for Respiratory Failure) study investigators are listed in the online supplement. Supported by grants from the NHLBI and the National Institute of Nursing Research, NIH (U01 HL086622 [M.A.Q.C.] and U01 HL086649 [D.W.]). Author Contributions: All authors fulfill authorship criteria through substantial contributions to conception or design of the study; acquisition, analysis, or interpretation of the data; and manuscript drafting or critical revision of the manuscript for important intellectual content. M.A.Q.C. and D.W. had full access to all of the data and take responsibility for data integrity and analytic accuracy.
Publisher Copyright:
Copyright © 2018 by the American Thoracic Society.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Rationale: Extracorporeal membrane oxygenation (ECMO) has supported gas exchange in children with severe respiratory failure for more than 40 years, without ECMO efficacy studies. Objectives: To compare the mortality and functional status of children with severe acute respiratory failure supported with and without ECMO. Methods: This cohort study compared ECMO-supported children to pair-matched non–ECMO-supported control subjects with severe acute respiratory distress syndrome (ARDS). Both individual case matching and propensity score matching were used. The study sample was selected from children enrolled in the cluster-randomized RESTORE (Randomized Evaluation of Sedation Titration for Respiratory Failure) clinical trial. Detailed demographic and daily physiologic data were used to match patients. The primary endpoint was in-hospital mortality. Secondary outcomes included hospital-free days, ventilator-free days, and change in functional status at hospital discharge. Measurements and Main Results: Of 2,449 children in the RESTORE trial, 879 (35.9%) non–ECMO-supported patients with severe ARDS were eligible to match to 61 (2.5%) ECMO-supported children. When individual case matching was used (60 matched pairs), the in-hospital mortality rate at 90 days was 25% (15 of 60) for both the ECMO-supported and non–ECMO-supported children (P . 0.99). With propensity score matching (61 matched pairs), the ECMO-supported in-hospital mortality rate was 15 of 61 (25%), and the non–ECMO-supported hospital mortality rate was 18 of 61 (30%) (P = 0.70). There was no difference between ECMO-supported and non–ECMO-supported patients in any secondary outcomes. Conclusions: In children with severe ARDS, our results do not demonstrate that ECMO-supported children have superior outcomes compared with non–ECMO-supported children. Definitive answers will require a rigorous multisite randomized controlled trial.
AB - Rationale: Extracorporeal membrane oxygenation (ECMO) has supported gas exchange in children with severe respiratory failure for more than 40 years, without ECMO efficacy studies. Objectives: To compare the mortality and functional status of children with severe acute respiratory failure supported with and without ECMO. Methods: This cohort study compared ECMO-supported children to pair-matched non–ECMO-supported control subjects with severe acute respiratory distress syndrome (ARDS). Both individual case matching and propensity score matching were used. The study sample was selected from children enrolled in the cluster-randomized RESTORE (Randomized Evaluation of Sedation Titration for Respiratory Failure) clinical trial. Detailed demographic and daily physiologic data were used to match patients. The primary endpoint was in-hospital mortality. Secondary outcomes included hospital-free days, ventilator-free days, and change in functional status at hospital discharge. Measurements and Main Results: Of 2,449 children in the RESTORE trial, 879 (35.9%) non–ECMO-supported patients with severe ARDS were eligible to match to 61 (2.5%) ECMO-supported children. When individual case matching was used (60 matched pairs), the in-hospital mortality rate at 90 days was 25% (15 of 60) for both the ECMO-supported and non–ECMO-supported children (P . 0.99). With propensity score matching (61 matched pairs), the ECMO-supported in-hospital mortality rate was 15 of 61 (25%), and the non–ECMO-supported hospital mortality rate was 18 of 61 (30%) (P = 0.70). There was no difference between ECMO-supported and non–ECMO-supported patients in any secondary outcomes. Conclusions: In children with severe ARDS, our results do not demonstrate that ECMO-supported children have superior outcomes compared with non–ECMO-supported children. Definitive answers will require a rigorous multisite randomized controlled trial.
KW - Acute respiratory distress syndrome
KW - Extracorporeal life support
KW - Extracorporeal membrane oxygenation
KW - Pediatric acute respiratory distress syndrome
KW - Propensity score analysis
UR - http://www.scopus.com/inward/record.url?scp=85046537078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046537078&partnerID=8YFLogxK
U2 - 10.1164/rccm.201709-1893OC
DO - 10.1164/rccm.201709-1893OC
M3 - Article
C2 - 29373797
AN - SCOPUS:85046537078
VL - 197
SP - 1177
EP - 1186
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
SN - 1073-449X
IS - 9
ER -